Title

Y-Addiction Series :

A Hybrid model of

Dopamine Capping, Serotonin Substitution,

and Biosensor Monitoring for Drug Addiction

Author
Y OH
Independent Researcher
ORCID: 0009-0000-0097-433X

Abstract

Drug addiction imposes profound medical, psychological, and social burdens worldwide. Conventional interventions, focusing solely on suppression or substitution, frequently show poor adherence and high relapse rates. This preprint proposes an integrated framework consisting of: (1) **Dopamine Capping**, which sets an upper limit on reward-circuit activation; (2) **Serotonin Substitution**, which offsets anhedonia caused by suppression through serotonin- and oxytocin-based pathways; and (3) **Implantable Biosensor Monitoring**, enabling continuous detection of abnormal neurophysiological signals and early intervention. This hybrid model provides a dual safeguard by reducing relapse risk and improving compliance while also opening possibilities for policy-level applications. Further validation through animal models, human trials, and computational psychiatry is required.

1. Introduction

Drug addiction is sustained by maladaptive learning within the dopamine reward circuitry, particularly through exaggerated reward prediction errors. Current treatments follow two main strategies:

- **Suppression-based** approaches, aiming to reduce craving intensity;

- **Substitution-based** approaches, such as methadone or buprenorphine replacement, or psychosocial substitutes.

However, suppression alone often leads to anhedonia and low adherence, while substitution alone fails to control dopamine surges, leaving relapse risk high. A combined approach is therefore necessary.

This paper builds upon the **author's previous framework for alcohol dependence**, which introduced serotonin-based substitution as a core mechanism for long-term self-regulation. In the present model for drug addiction, that foundational substitution layer is retained, but two additional components are introduced: (1) **dopamine capping** to limit excessive reward signaling, and (2) **implantable biosensor monitoring** to enable real-time relapse detection and intervention. This triadic system aims to provide a more robust, personalized, and sustainable approach to severe substance dependence.

This preprint expands the **author's prior model** for **alcohol dependence (OH, 2025),** adapting its **core substitution principle** to more severe forms of substance addiction while adding two new structural components.\

2. Theoretical Basis



※ Conceptual Framework: Multi-Layered Reward Circuit Intervention

2.1 Natural capping phenomena

Long-term drug use results in downregulation of dopamine receptors (D2/D3), producing diminished effects at the same dose. This can be seen as a naturally imposed "cap" within the reward system.

2.2 Artificial capping interventions

Partial dopamine receptor antagonists (e.g., aripiprazole) can pharmacologically limit dopamine signaling beyond a certain threshold. This principle can be extended into a therapeutic strategy.

2.3 Substitution pathways

Pure dopamine suppression risks severe anhedonia. Thus, serotonin- and oxytocin-mediated substitutes—via SSRIs, microdosing of psychedelics, or social bonding activities—may compensate for reward deficits and sustain compliance.

3. Core Model

3.1 Dopamine Capping

- **Objective**: Prevent excessive dopaminergic activation.
- **Method**: Low-dose receptor antagonists, neuromodulation (non-invasive or closed-loop DBS).
- **Effect**: Reduction of dopamine spikes → lowered relapse triggers.

3.2 Serotonin Substitution

- **Objective**: Compensate for deficits from dopamine suppression.
- **Method**: SSRIs, serotonergic agonists, oxytocin-enhancing interventions.
- **Effect**: Establish alternative satisfaction loops → improved treatment adherence.

3.3 Implantable Biosensor Monitoring

- **Design**: Subcutaneous implant (analogous to contraceptive implants such as Implanon).
- **Functions**:
  - Monitor biomarkers (dopamine-related metabolites, HRV, EEG patterns).
  - Send alerts to treatment centers if thresholds are exceeded.
  - Optionally release micro-doses of modulatory agents.
- **Purpose**: Not punitive, but therapeutic and preventive.

- Recent advances in consumer **EEG devices** such as **Kernel Flow**, **Muse S**, and **Neurable** demonstrate the feasibility of real-time neurofeedback systems. These technologies can detect EEG signals associated with reward anticipation (e.g., **theta bursts**, **P300 changes**) and trigger personalized digital interventions, such as calming stimuli or behavioral redirection, based on AI analysis.

4. Experimental Framework

4.1 Animal models

- **Subjects**: Rodents with cocaine/methamphetamine dependence.
- **Groups**: (a) Capping only, (b) Cap + Substitution combined, (c) Control.
- **Measures**: Self-administration frequency, dopaminergic activity (microdialysis), behavioral markers.

4.2 Human pilot models (hypothetical)

- **Subjects**: High-risk relapse patients.
- **Intervention**: Personalized capping + substitution + subcutaneous sensor.
- **Measures**: PET-based dopamine release thresholds, craving scales, relapse rates, quality of life.

4.3 Computational psychiatry models

- Reinforcement learning (RL) with imposed upper limits on reward prediction error.
- Expected outcome: Flattened craving curves, reduced impulsivity.

5. Policy and Ethical Considerations

- Voluntary participation prioritized; high-risk cases may involve supervised application.
- Data security ensured through encryption and anonymization.
- Device reversibility and safety must be guaranteed, with informed consent as a prerequisite.
- Ethical debate remains regarding free will vs. social safety.

6. Strengths and Limitations

- Strengths

    1. **Dual safeguard**: Suppression plus substitution reduces relapse more effectively.
    2. **Early-warning system**: Real-time monitoring enables rapid intervention.
    3. **Personalization**: Adaptive to individual neurochemical variability.
    4. **Social impact**: Potential reduction of incarceration costs and healthcare burden.
    5. **Scalability**: Applicable to behavioral addictions (e.g., gambling, gaming).

- Limitations

1. **Inter-individual variability**: Dopamine receptor sensitivity differs, making standardization difficult.
2. **Technological immaturity**: Implantable sensor–drug delivery systems remain untested in addiction.
3. **Proxy measurement limits**: Direct dopamine monitoring is not yet clinically feasible.
4. **Ethical controversies**: Bodily implants and data privacy raise concerns.
5. **Incomplete substitution**: Serotonin/oxytocin-based pathways may not fully replace dopaminergic reward.

7. Translational Inspiration: From Glucose Spikes to Dopamine Surges

The initial conceptual inspiration for this framework came not from addiction medicine, but from the metabolic management of diabetes.

In particular, **Continuous Glucose Monitoring (CGM) systems** inspired **the idea** that neurochemical fluctuations **such as dopamine spikes** could also be tracked and modulated in real time. **CGM devices** monitor blood sugar levels and alert patients to act before reaching dangerous thresholds.

This gave rise to the **hypothesis that addiction**, too, could be **approached as** a dynamic, monitorable process rather than a fixed behavioral defect. The architecture of this model especially the biosensor module reflects this translational perspective.

8. Conclusion

This paper introduces a **hybrid model combining dopamine capping, serotonin substitution, and implantable biosensor monitoring** as a novel intervention for severe drug addiction. The model addresses shortcomings of suppression- or substitution-only paradigms, while enabling early-warning and personalized care. Although preliminary, this framework highlights a promising direction for clinical trials and public policy, with the potential to reduce relapse and mitigate the societal costs of addiction.

Ultimately, the root of all addiction may lie in the unregulated volatility of the dopaminergic system. This includes not only substance-based addictions alcohol, nicotine, opioids, stimulants but also behavioral forms such as **gambling, pornography, video gaming**, social media use, **compulsive shopping, binge eating, and workaholism**. All of these rely on the same core mechanism: **dopamine-mediated reward anticipation and reinforcement**.

By capping dopamine surges, substituting with serotonin-oxytocin pathways, and applying real-time biosensor intervention, this model offers more than just treatment—it proposes a **generalizable blueprint for rewiring human craving at its neurobiological core**.

If implemented systemically, the approach may not only reduce relapse rates but **redefine addiction itself as a solvable, containable condition**. In an ideal future, the term *addiction* may become an artifact—**a vanishing species in the ecosystem of human dysfunction**, no longer endemic but archived, studied, and remembered like the extinct predators of mental health.

---

8. References

1. Koob, G. F., & Volkow, N. D. (2016). Neurobiology of addiction: a neurocircuitry analysis. ***The Lancet Psychiatry**, 3*(8), 760–773.

2. Volkow, N. D., & Morales, M. (2015). The brain on drugs: from reward to addiction. *Cell, 162*(4), 712–725.

3. O'Brien, C. (2008). Evidence-based treatments of addiction. ***Philosophical Transactions of the Royal Society B: Biological Sciences**, 363*(1507), 3277–3286.

4. Carhart-Harris, R. L., & Goodwin, G. M. (2017). The therapeutic potential of psychedelic drugs: past, present, and future. ***Neuropsychopharmacology**, 42*(11), 2105–2113.

5. Resnick, S. M., & Griffiths, R. R. (2021). Ethical considerations in neuromodulation for psychiatric disorders. ***Nature Reviews Neuroscience**, 22*(10), 621–635.

6. United Nations Office on Drugs and Crime (UNODC). (2023). ***World Drug Report** 2023*.

7. OH, Y. (2025). ***Two-Step Transition Model for Alcohol Dependence**: From Substitution to Self-Regulation*. Zenodo. https://doi.org/10.5281/zenodo.17082268